Drug intelligence / Profile preview

cetirizine + theophylline

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of cetirizine, an H1-receptor antagonist, and theophylline, a non-specific phosphodiesterase inhibitor. This combination has been studied for the treatment of chronic idiopathic urticaria (CIU), where theophylline provides additional benefit when added to cetirizine therapy. The interaction between these two drugs is minimal and not considered clinically significant.

Targets

ADOR (Adenosine receptors)PDE (Phosphodiesterase family)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on cetirizine + theophylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetirizine + theophylline.

Explore the full profile